Chronic myelogenous leukemia (CML) is characterized by the oncogenic fusion protein, BCR-ABL protein kinase, against which clinically useful inhibitors have been developed. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.